X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PANACEA BIOTECH - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PANACEA BIOTECH DISHMAN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 -21.1 - View Chart
P/BV x 3.3 2.5 134.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
DISHMAN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs374149 251.8%   
Low Rs12982 156.6%   
Sales per share (Unadj.) Rs197.884.1 235.1%  
Earnings per share (Unadj.) Rs21.2-18.3 -115.8%  
Cash flow per share (Unadj.) Rs34.7-6.7 -518.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.983.7 214.9%  
Shares outstanding (eoy) m80.6961.25 131.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.4 92.7%   
Avg P/E ratio x11.9-6.3 -188.1%  
P/CF ratio (eoy) x7.2-17.2 -42.0%  
Price / Book Value ratio x1.41.4 101.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3067,074 287.0%   
No. of employees `0000.82.8 30.1%   
Total wages/salary Rs m5,3551,449 369.5%   
Avg. sales/employee Rs Th19,252.71,874.1 1,027.3%   
Avg. wages/employee Rs Th6,459.5527.0 1,225.7%   
Avg. net profit/employee Rs Th2,064.1-407.7 -506.2%   
INCOME DATA
Net Sales Rs m15,9615,154 309.7%  
Other income Rs m265100 265.9%   
Total revenues Rs m16,2265,254 308.9%   
Gross profit Rs m4,103-766 -535.5%  
Depreciation Rs m1,091711 153.4%   
Interest Rs m9441,503 62.8%   
Profit before tax Rs m2,334-2,881 -81.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m1-6 -19.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m62417 3,711.9%   
Profit after tax Rs m1,711-1,121 -152.6%  
Gross profit margin %25.7-14.9 -172.9%  
Effective tax rate %26.7-0.6 -4,581.8%   
Net profit margin %10.7-21.8 -49.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,810 289.2%   
Current liabilities Rs m9,5178,365 113.8%   
Net working cap to sales %9.4-88.4 -10.6%  
Current ratio x1.20.5 254.2%  
Inventory Days Days110156 71.0%  
Debtors Days Days3567 51.8%  
Net fixed assets Rs m16,30414,480 112.6%   
Share capital Rs m16161 263.3%   
"Free" reserves Rs m12,907903 1,429.2%   
Net worth Rs m14,5165,127 283.1%   
Long term debt Rs m4,1895,832 71.8%   
Total assets Rs m29,80519,433 153.4%  
Interest coverage x3.5-0.9 -378.7%   
Debt to equity ratio x0.31.1 25.4%  
Sales to assets ratio x0.50.3 201.9%   
Return on assets %8.92.0 453.6%  
Return on equity %11.8-21.9 -53.9%  
Return on capital %17.53.6 482.1%  
Exports to sales %24.824.5 101.1%   
Imports to sales %3.710.2 36.7%   
Exports (fob) Rs m3,9561,264 313.0%   
Imports (cif) Rs m596525 113.6%   
Fx inflow Rs m4,9521,539 321.7%   
Fx outflow Rs m697942 74.0%   
Net fx Rs m4,255597 712.4%   
CASH FLOW
From Operations Rs m2,786599 465.0%  
From Investments Rs m-1,529-438 349.1%  
From Financial Activity Rs m-941-303 311.0%  
Net Cashflow Rs m316-141 -223.9%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 12.7 1.3 976.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.6 93.6%  
Shareholders   46,261 10,259 450.9%  
Pledged promoter(s) holding % 35.8 35.1 102.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS